Elranatamab reduced the risk of disease progression or death vs standard care in patients with R/R myeloma after prior anti-CD38 therapy and lenalidomide.
|Videos|January 2, 2018
Exploring the Use of Liquid Biopsies in Smoldering Multiple Myeloma
Author(s)Mark W. Bustoros, MD
Mark W. Bustoros, MD, a postdoctoral fellow at Dana-Farber Cancer Institute, Harvard Medical School, discusses ongoing research exploring the use of liquid biopsies in patients with smoldering multiple myeloma.
Advertisement
Advertisement
Related to this article
New study shows CT-measured body fat, not BMI, links obesity to higher lung cancer risk via immune T-cell changes—hinting at prevention through weight loss.
Etentamig, a BCMAxCD3 bispecific antibody, was submitted for potential FDA approval based on the phase 3 CERVINO trial in relapsed/refractory multiple myeloma.
During a live event, Robert Orlowski, MD, PhD, and participants discussed how access barriers, disease tempo, and bridging choices shape CAR T referral for a patient with early relapsed multiple myeloma.
The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
At Rutgers Cancer Institute, neuro-oncologists met to discuss the latest trends in precision brain cancer care with FET-PET imaging, advanced molecular testing, and same-day multidisciplinary clinics.
During a virtual event, Thomas Martin, MD, and participants considered the use of the on-body injector for subcutaneous isatuximab for a frail patient with transplant-ineligible newly diagnosed myeloma.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
3
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
4
Petosemtamab Plus Pembrolizumab Improves OS in PD-L1+ HNSCC
5